Skip to main content

Oncology · United Kingdom

Cancer immunotherapy in the UK, by a consultant medical oncologist.

Checkpoint inhibitors, CAR-T, bispecifics, ADCs and cancer vaccines - the whole immuno-oncology map, mapped to your diagnosis, your biomarkers and either the NICE / CDF route or a private prescription.

A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Indicative pricing

What private immunotherapy costs in the UK.

Indicative per-cycle ranges across our partner oncology centres. NHS access through NICE / CDF / Blueteq is fully funded - we tell you which route applies.

In short

A pembrolizumab or nivolumab cycle privately: £8,000–£14,000, given every three weeks.

Regimen Indicative range
Anti-PD-1 (pembrolizumab / nivolumab) per cycle £8,000–£14,000
Anti-PD-L1 (atezolizumab / durvalumab) per cycle £4,000–£9,000
Ipilimumab + nivolumab combination per cycle £15,000–£25,000
Bispecific (teclistamab / glofitamab) step-up £12,000–£20,000 per cycle
CAR-T (single infusion, tariff) £280,000–£380,000
Consultant oncology review £300–£500

Prices vary by centre, drug indication, cycle length and whether the patient is on monotherapy or a combination. CAR-T is delivered only at JACIE-accredited centres and always requires MDT approval.

The problem

The right drug, the right access route, the right safety net.

Immuno-oncology moves fast - the 2026 UK landscape has more than thirty licensed products across eight drug classes. Working out which one applies to your case, whether NICE or the CDF funds it, and where to be treated is genuinely difficult.

  • Not sure which drug is licensed?

    PD-L1, MSI-H, TMB and HER2 all change the answer. We map biomarkers to the licensed indication for your tumour type.

  • NICE, CDF or private?

    Most licensed indications are funded on the NHS via NICE or the Cancer Drugs Fund with Blueteq authorisation. We explain the route in plain English.

When it helps

The cancers immunotherapy treats in 2026.

The main licensed indications in the UK, plus the one red flag that turns a routine call into an emergency.

  • Melanoma (adjuvant or advanced)

    Stage III adjuvant pembrolizumab or nivolumab; advanced disease treated with ipi+nivo or nivo+relatlimab.

  • NSCLC (adjuvant + advanced)

    PD-L1 tested tumours; pembrolizumab, atezolizumab, cemiplimab, tislelizumab or durvalumab per stage and expression.

  • Renal, bladder and urothelial cancers

    Advanced RCC on ipi+nivo or pembro+axitinib; urothelial on avelumab maintenance or pembrolizumab.

  • MSI-H / dMMR tumours (any site)

    Endometrial, colorectal and other MSI-H cancers respond well to pembrolizumab or dostarlimab - biomarker-driven access.

  • Haematological cancers (DLBCL, MM, ALL)

    CAR-T (Yescarta, Kymriah, Carvykti, Aucatzyl) and bispecifics (glofitamab, teclistamab, epcoritamab) for relapsed disease.

  • Head & neck, cervical and TNBC

    Recurrent/metastatic H&N SCC, cervical and triple-negative breast cancers with PD-L1-positive tumours.

  • Rare tumours (Merkel, cSCC, mesothelioma)

    Avelumab for Merkel cell, cemiplimab for cutaneous SCC, ipi+nivo for mesothelioma - small trials, big responses.

  • Red flag: new breathlessness or chest pain

    Pneumonitis and myocarditis are irAE emergencies - call the 24-hour oncology line the same day, not a routine appointment.

Drug classes

Eight classes of cancer immunotherapy, in plain English.

What each family of drugs actually does, and the UK-licensed products in each - from the household names to the 2024–2026 launches.

  • Anti-PD-1 checkpoint inhibitors

    Pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Libtayo), dostarlimab (Jemperli), tislelizumab (Tevimbra) - the workhorses of solid-tumour immunotherapy.

  • Anti-PD-L1 checkpoint inhibitors

    Atezolizumab (Tecentriq), durvalumab (Imfinzi), avelumab (Bavencio) - often paired with chemotherapy or targeted agents.

  • Anti-CTLA-4 and anti-LAG-3

    Ipilimumab (Yervoy) and tremelimumab (Imjudo) release T-cell brakes; relatlimab (Opdualag with nivolumab) targets LAG-3 in melanoma.

  • Combination checkpoint therapy

    Ipi+nivo (melanoma, RCC, mesothelioma, MSI-H CRC, NSCLC); durva+treme (HCC, NSCLC); nivo+relatlimab (melanoma). Higher response, higher irAE risk.

  • CAR-T cellular therapy

    Tisagenlecleucel, axi-cel, brexu-cel, liso-cel, ide-cel, cilta-cel and Aucatzyl (2024 UK-first BCMA CAR-T) - one-shot living drugs for DLBCL, ALL, MCL and myeloma.

  • Bispecific T-cell engagers (BiTEs)

    Blinatumomab (ALL), teclistamab / elranatamab / talquetamab (myeloma), glofitamab / epcoritamab (DLBCL/FL), mosunetuzumab (FL), tarlatamab (SCLC DLL3).

  • Oncolytic virus and cancer vaccines

    Talimogene laherparepvec (T-VEC, Imlygic) for melanoma; personalised neoantigen mRNA vaccines (mRNA-4157 + pembrolizumab) currently in NICE review.

  • Antibody-drug conjugates (ADCs)

    Trastuzumab deruxtecan (Enhertu), sacituzumab govitecan (Trodelvy), enfortumab vedotin (Padcev), datopotamab deruxtecan - immune-target delivery of chemotherapy.

Safety and side effects

Immune-related adverse events - honestly.

Immunotherapy is one of the most effective advances in cancer care of the last decade - but its side effects are different from chemotherapy, sometimes irreversible, and occasionally life-threatening. Knowing what to watch for is the difference.

  • Immune-related adverse events (irAEs)

    Any organ can be affected - skin, gut, thyroid, pituitary, liver, lungs, heart, kidneys, joints and nerves. Most are grade 1–2 and respond to steroids; grade 3–4 need admission.

  • Pneumonitis is the one that kills

    New breathlessness, dry cough or a drop in oxygen saturation on a home probe - same-day CT and IV methylprednisolone. Do not wait for the next clinic.

  • Myocarditis is rare but often fatal

    Baseline and periodic troponin monitoring is now standard. Chest pain, palpitations or breathlessness after a checkpoint inhibitor is a same-day A&E visit.

  • Endocrine irAEs are often permanent

    Thyroiditis, hypophysitis, adrenal insufficiency and immune-mediated type 1 diabetes usually mean lifelong hormone replacement - not a reason to stop treatment.

  • Colitis is the commonest ipi+nivo toxicity

    More than three loose stools above baseline is grade 2 - hold the drug, start prednisolone. Steroid-refractory colitis is treated with infliximab or vedolizumab.

  • CAR-T brings CRS and ICANS

    Cytokine release syndrome (fever, hypotension) and immune-effector-cell-associated neurotoxicity - managed inpatient with tocilizumab, steroids and supportive care.

  • Secondary cancers - an FDA signal (2024)

    A small, real signal of secondary T-cell malignancies after CAR-T. Discussed at consent; monitored lifelong; benefit still outweighs risk in relapsed disease.

  • Cost and access - NICE, CDF, Blueteq

    NHS access runs through the NICE TA, the Cancer Drugs Fund and Blueteq authorisation. Private prescription is £10–20k per cycle for most ICIs.

  • Red flags after any dose

    Breathlessness, chest pain, severe diarrhoea, jaundice, a new severe headache or unusual fatigue - call the 24-hour oncology hotline, not your GP.

Reading your treatment plan

Your oncology plan in four parts. Read the last one first.

Whichever agent is chosen, the plan the oncologist sends you keeps to the same shape.

A UK consultant medical oncologist reviewing an immunotherapy treatment plan

A quiet reminder

Oncology language is precise and can read coldly - we translate it for you.

If you would like us to talk you through the plan before your first cycle, just ask.

  1. 01 Header

    Diagnosis, biomarkers and line of therapy

    Tumour type, stage, PD-L1 CPS/TPS, MSI status, TMB, HER2 and previous treatment lines - the four inputs that decide which agent is licensed.

  2. 02 Regimen

    Drug, dose, schedule and duration

    The chosen agent (pembrolizumab, ipi+nivo, teclistamab, etc.), dose, cycle length, maximum duration and whether it is monotherapy or a combination.

  3. 03 Monitoring

    Baseline bloods and irAE surveillance plan

    Baseline TFTs, cortisol, troponin, LFTs, glucose and lung function; the pre-cycle blood set; and the imaging schedule for response assessment.

  4. 04 Impression

    Access route, cost and safety-net contact

    Read this first: NHS via NICE/CDF, private self-pay per cycle, and the 24-hour oncology number for any irAE symptom.

Recognised by major UK insurers

BupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealix

Private insurance cover for immunotherapy varies by insurer, tumour type and whether the drug is NICE-approved.

Frequently asked

Everything we get asked about cancer immunotherapy.

Quick answers on funding, side effects, cycle length and when to call the oncology hotline.

  • What is cancer immunotherapy?

    A group of treatments that use your own immune system to attack cancer. It covers checkpoint inhibitors (pembrolizumab, nivolumab), CAR-T cell therapy, bispecific antibodies, oncolytic viruses, cancer vaccines and antibody-drug conjugates. It is not chemotherapy and it works very differently - including its side effects.

  • Is immunotherapy funded on the NHS?

    Yes, for most licensed indications, via the NICE technology appraisal (TA) route or the Cancer Drugs Fund (CDF) with Blueteq authorisation. Access depends on tumour type, stage and biomarkers (PD-L1, MSI-H/dMMR, TMB).

  • How much does private immunotherapy cost in the UK?

    Roughly £8,000–£14,000 per cycle for pembrolizumab or nivolumab; £4,000–£9,000 for atezolizumab or durvalumab; £15,000–£25,000 for ipilimumab + nivolumab combinations. CAR-T is a single infusion at a tariff of £280,000–£380,000. Bispecifics for haematological cancers run £12,000–£20,000 per cycle.

  • How is it given?

    Most checkpoint inhibitors are IV infusions of 30–60 minutes every 2–6 weeks in an oncology day unit. Newer subcutaneous formulations of atezolizumab and nivolumab are now available. CAR-T is a single infusion after apheresis. Bispecifics start with inpatient step-up dosing.

  • What are immune-related adverse events (irAEs)?

    Immunotherapy can inflame any organ. Common: rash, thyroid dysfunction, colitis, hepatitis. Serious: pneumonitis, myocarditis, hypophysitis, type 1 diabetes, Guillain-Barré. Most are managed with steroids; some are irreversible. Any new breathlessness, chest pain or severe diarrhoea after a dose is a same-day call to the oncology hotline.

  • How long does immunotherapy treatment last?

    Adjuvant checkpoint inhibitors are usually given for 12 months. Advanced-disease treatment is often continued for up to two years or until disease progression or intolerable toxicity. CAR-T is a single infusion. Bispecifics are given until progression or toxicity.

  • Will immunotherapy work for my cancer?

    It depends on tumour type and biomarkers. Melanoma, NSCLC, RCC, MSI-H tumours, Hodgkin lymphoma and Merkel cell cancer respond well. PD-L1, MSI/dMMR and TMB testing on tumour tissue guides the decision. Response rates range from 15% (some solid tumours) to over 80% (Hodgkin, MSI-H).

  • What is CAR-T and who is it for?

    CAR-T (chimeric antigen receptor T-cell therapy) is a one-shot living drug for relapsed/refractory B-cell lymphoma, acute lymphoblastic leukaemia and multiple myeloma. UK-licensed products include Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti and Aucatzyl (the first UK-developed BCMA CAR-T, 2024).

  • When should I call the oncology hotline?

    Same-day for: new breathlessness or a drop in home oximetry, chest pain or palpitations, more than four loose stools above baseline, jaundice, a new severe headache, extreme fatigue or dizziness on standing. Do not wait for your next clinic appointment - irAEs escalate quickly.

Related treatments

Looking for something else?